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Abstract
Background: The paucity of controlled data for the treatment of most biliary sphincter of Oddi disorder (SOD)
types and the incomplete response to therapy seen in clinical practice and several trials has generated controversy
as to the best course of management of these patients. In this observational study we aimed to assess the
outcome of patients with biliary SOD managed without sphincter of Oddi manometry.
Methods: Fifty-nine patients with biliary SOD (14% type I, 51% type II, 35% type III) were prospectively enrolled. All
patients with a dilated common bile duct were offered endoscopic retrograde cholangiopancreatography (ERCP)
and sphincterotomy whereas all others were offered medical treatment alone. Patients were followed up for a
median of 15 months and were assessed clinically for response to treatment.
Results: At follow-up 15.3% of patients reported complete symptom resolution, 59.3% improvement, 22%
unchanged symptoms, and 3.4% deterioration. Fifty-one percent experienced symptom resolution/improvement on
medical treatment only, 12% after sphincterotomy, and 10% after both medical treatment/sphincterotomy. Twenty
percent experienced at least one recurrence of symptoms after initial response to medical and/or endoscopic
treatment. Fifty ERCP procedures were performed in 24 patients with an 18% complication rate (16% post-ERCP
pancreatitis). The majority of complications occurred in the first ERCP these patients had. Most complications were
mild and treated conservatively. Age, gender, comorbidity, SOD type, dilated common bile duct, presence of intact
gallbladder, or opiate use were not related to the effect of treatment at the end of follow-up (p > 0.05 for all).
Conclusions: Patients with biliary SOD may be managed with a combination of endoscopic sphincterotomy
(performed in those with dilated common bile duct) and medical therapy without manometry. The results of this
approach with regards to symptomatic relief and ERCP complication rate are comparable to those previously
published in the literature in cohorts of patients assessed by manometry.
Background
Sphincter of Oddi disorder (SOD) is a syndrome invol-
ving recurrent abdominal pain, with or without abnorm-
alities in liver or pancreatic chemistries or duct
dilatation. The paucity of controlled data for the treat-
ment of most biliary SOD types and the incomplete
response to therapy seen in clinical practice as well as in
several trials [1-3], has generated significant controversy
as to what the best course of management of these
patients is. Consensus opinion holds that patients with
biliary SOD type I, presenting with abdominal pain,
raised liver function tests, and dilated common bile duct
(CBD), should be treated with papillary decompression
by means of endoscopic or surgical sphincterotomy
[4,5]. However, the appropriate management of patients
with biliary SOD type II and III remains unresolved.
Current recommendations, based on two randomized
controlled trials, include the use of sphincter of Oddi
manometry (SOM) in patients with SOD type II so that
sphincterotomy may be performed only in those with
elevated pressure [5]. The results of these trials, how-
ever, are not in agreement with those of several uncon-
trolled studies in which outcome was not found to be
associated with SOM findings [6-8]. There is no firm
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SOD type III who should be carefully evaluated and
treated pharmacologically prior to considering SOM and
sphincterotomy [5].
Suspected sphincter of Oddi dysfunction has been
shown in several studies to be related to increased com-
plication risk at endoscopic retrograde cholangiopan-
creatography (ERCP) and SOM/sphincterotomy [9-11].
Thus, the potential benefits should be weighed against
this increased complication risk prior to any attempt to
treat SOD with endoscopic sphincterotomy.
The aim of the current study was to evaluate the nat-




All consecutive patients diagnosed with biliary SOD who
were reviewed in the outpatient clinic of the Depart-
ment of Gastroenterology at the John Radcliffe Hospital
in Oxford, UK during the period October 2003 - Sep-
tember 2008 were prospectively identified and enrolled
in the study. The diagnosis of biliary SOD was estab-
lished according to the Rome II [12] or, after 2006, the
Rome III criteria [5]. Other causes of abdominal pain
were excluded by means of endoscopic and imaging
investigations as clinically indicated. All patients had
had a trial of proton pump inhibitors for at least four
weeks that had been ineffective. Transabdominal ultra-
sound and magnetic resonance cholangiopancreatogra-
phy (MRCP) were performed on all patients. Patients
were categorized, according to the modified Geenen-
Hogan biliary classification, into type I (dilated CBD (≥6
mm on ultrasound or MRCP) and abnormal aspartate
aminotransferase, alanine aminotransferase, bilirubin, or
alkaline phosphatase > 2 times normal values on 2 or
more occasions), II (dilated CBD or any of the pre-
viously mentioned laboratory abnormalities), or III
(none of the previously mentioned laboratory or imaging
criteria) [5]. Patients with pancreatic SOD alone, pan-
creas divisum, pancreaticobiliary malignancy, recurrent
pancreatitis, or any other potential cause of abdominal
pain identified during routine clinical investigations
were excluded from the study. No patient had gallblad-
der or bile duct stones or sludge on imaging or ERCP.
No patient had abnormal pancreas or pancreatic duct
on imaging or raised pancreatic amylase.
Management
Following initial evaluation, patients with a clinical diag-
nosis of SOD type I and type II with dilated CBD were
offered the option of biliary sphincterotomy or medical
therapy. Medical treatment consisted of low dose ami-
tryptiline (10-50 mg OD) followed by nifedipine (20 mg
OD) [13] and glyceril trinitrate (GTN) spray. Regular
pain relief medications such as paracetamol (500 mg 1-2
tablets QDS prn), tramadol (50-100 mg TDS prn), and
codeine phosphate (30 mg 1-2 tablets QDS prn) were
also used as needed alone or in combination with the
previously mentioned medications. Patients with SOD
type I and type II with a dilated CBD who initially
opted for medical treatment but experienced symptom
persistence after 3-6 months’ follow-up were offered
biliary sphincterotomy. Patients with SOD II with non-
dilated CBD as well as patients with SOD III were
offered medical treatment alone as described above.
Patients with no satisfactory symptom relief after the
above strategy were referred to a dedicated pain relief
service. The management of patients with a clinical
diagnosis of biliary SOD is summarized in Figure 1.
Follow-up and data collection
Patient files were scrutinized and the following clinical data
were extracted: age at diagnosis, gender, follow-up time
(time from diagnosis until last outpatient clinic visit during
the study period, until discharge or until last clinic visit
before being lost to follow-up), imaging findings, treatment
modalities used for SOD and their effect on symptoms as
documented in the patient notes, comorbidities, and medi-
cations. In particular, the number of ERCPs performed in
each patient case as well as the indication, any therapeutic
Figure 1 Flow chart of the management of the current cohort
of patients with a clinical diagnosis of SOD (n = 59)
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complications were registered. No prophylaxis by means of
anti-proteasic drugs was given. Post-ERCP complications
and their severity were defined as previously described
[10]. The study protocol was approved by the Milton Key-
nes Research Ethics Committee and written informed con-
sent was obtained by all patients.
Statistics
Data are presented as median and interquartile range
(IQR) or n and % as appropriate. The Mann-Whitney U
test was performed for calculations of differences
between groups. The Fisher’se x a c tt e s tw a su s e df o r
comparison between qualitative variables. All tests were
two tailed and conducted at a 5% significance level.
Results
Basic patient characteristics are shown in table 1. By the end
of the study period, 14/59 patients (23%) were discharged
from the outpatient clinic, 8/59 (14%) were lost to follow-
up, and 37/59 (63%) were still under active follow-up. Over-
all, 33/59 (56%) of patients had an intact gallbladder.
Effect of medical and endoscopic therapy
The management and outcome of all patients with a
clinical diagnosis of biliary SOD is shown in table 2.
Overall, at last follow-up 9/59 patients (15.3%) reported
complete symptom resolution, 35/59 (59.3%) improve-
ment, 13/59 (22%) unchanged symptoms, and 2/59
(3.4%) symptom deterioration. Thirty out of 59 (51%) of
patients experienced symptom resolution or improve-
ment on medical treatment only, 7/59 (12%) after
ERCP/sphincterotomy, and 6/59 (10%) after both medi-
cal treatment and ERCP/sphincterotomy. One patient
experienced spontaneous symptom resolution with no
particular treatment 6 months after presentation. Twelve
patients out of 59 (20%) experienced at least one recur-
rence of symptoms (range 1-4) after initial response to
medical and/or endoscopic treatment.
Medical interventions
In all, 21/59 (35.6%) patients experienced symptom
resolution or improvement on low-dose tricyclic antide-
pressants (mainly amitryptiline, in two cases in combi-
nation with GTN spray and in 2 other cases in
combination with tramadol), 3/59 (5%) on GTN spray,
2/59 on buscopan, 2/59 on morphine, and 1 each on
nifedipine, low-dose citalopram, low-dose venlafaxine,
diclofenac, paracetamol, tramadol, gabapentin (in combi-
nation with tramadol), and low-fat diet alone. Although
7/21 patients who were receiving opiates at baseline
were weaned off these medications, another 6 patients
were started on opiates (mainly tramadol) during the
follow-up period. Thus, by the last clinic review 20/59
(34%) of patients were on opiates.
ERCP and sphincterotomy
A total of 50 ERCP procedures were performed in 24/59
(41%) patients (range 1-7). Ten out of 24 patients (42%)
had only one ERCP performed but the rest (14/24) had
2-7 procedures during the follow-up period. Indications
for first ERCPs were intention to perform biliary sphinc-
terotomy (CBD ≥ 6 mm on ultrasound or MRCP) in all
patients apart from two who had an ERCP done as they
could not undergo MRCP due to claustrophobia. They
were both found to have dilated CBD and underwent
sphincterotomy. A third patient who was classified as
biliary SOD type III underwent ERCP and biliary
sphincterotomy after careful discussion of the expected
benefit and the risks of the procedure. No sphincterot-
omy or other intervention was performed in 1/24 of the
patients undergoing ERCP on which CBD dilation pre-
viously seen on MRCP, was not confirmed. Thus, 23/24
patients underwent endoscopic sphincterotomy (table 3).
In all, 14/23 patients (61%) undergoing ERCP/sphincter-
otomy reported initial symptom resolution/improvement
as a result of the ERCP interventions. However, symp-
tom recurrence/worsening after initial effect was
reported by 9/14 (64%) during follow-up. Recurrence
occurred after a mean of 13 months (median 18 months,
range 1-24 months) following endoscopic
Table 1 Basic characteristics of patients with biliary
sphincter of Oddi disorder (n = 59)
Age at diagnosis (years) 46 (37-59)
Women/Men 53/6 (90%/10%)
Follow-up (months) 15 (6-35)
Previous cholecystectomy 26 (44%)
Biliary SOD type
Type I 8 (14%)
Type II 30 (51%)
Dilated CBD 25 (42%)
Raised LFTs 5 (8%)
Type III 21 (35%)
Comorbidity
a 39 (66%)





Analgesics upon initial assessment 23 (39%)
Opiates upon initial assessment
d 21 (36%)
Data are presented as median and IQR or n and % as appropriate.
aPatients who had other types of disease apart from the sphincter of Oddi
disorder.
bEight patients out of 11 had depression and 3/11 anxiety.
cFive patients out of 10 had non-alcoholic fatty liver disease, 2/10 primary
biliary cirrhosis, 1/10 non-alcoholic steatohepatitis, 1/10 chronic hepatitis B,
and 1/10 chronic hepatitis C.
dEleven out of 21 patients were receiving codeine, 5/21 tramadol, 3/21
morphine, 1/21 morphine and tramadol, and 1/21 codeine and tramadol.
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with medications but further ERCP intervention was
performed in 6/9 patients. Three out of 6 patients
underwent pancreatic SOM and two were found to have
raised pancreatic sphincter pressures and, thus, received
pancreatic sphincterotomy. One of these recurred and
was referred for transduodenal sphincteroplasty with
good initial effect. Due to symptom recurrence during
follow-up she required medical treatment leading to
some pain relief (table 3, patient no 22). Another 3/6
patients underwent a trial of stenting. One was found to
have re-stenosis (scarring at the biliary orifice not allow-
ing the free passage of a small balloon (10-12 ml) and
underwent further biliary sphincterotomy following a
period of biliary stenting (table 3, patient no 19). The
other two patients who underwent biliary stenting were
found to have patent sphincterotomies (table 3, patients
no 20 and 21). One responded and was thus referred for
choledochojejunostomy with good initial effect. She
recurred during further follow-up and required medical
treatment leading to some pain relief (table 3, patient
no 21). The other patient did not respond to biliary
stenting and was referred to the pain relief team (table
3, patient no 20).
ERCP-related complications
All patients were routinely monitored as inpatients over-
night post-ERCP. In all, a complication occurred in 9
out of 50 procedures (18%). There was no post-ERCP
mortality. Eight patients had post-ERCP pancreatitis, 6/8
mild and 2/8 severe. Another patient had a retroperito-
neal perforation with contrast being injected into the
portal vein. She was treated conservatively as an inpati-
ent for 6 days. A total of 7/9 (78%) complications
occurred in the first ERCP each one of these patients
had. One out of 9 complications occurred in a second
and another in a third ERCP (pancreatitis in both cases).
A total of 6 out of 23 (26%) patients who underwent
endoscopic sphincterotomy experienced post-ERCP pan-
creatitis after their first ERCP.
Factors related to symptom resolution/improvement
during follow-up
Patients with symptom resolution/improvement had
been followed-up for longer periods of time compared
to patients with stable/deteriorated symptoms at the end
of follow-up (23 months (11-39) vs. 3 months (0-12), p
< 0.001). However, age at presentation, gender, comor-
bidity, other functional gastrointestinal disorder, psy-
chiatric disease, liver disease, opiates upon initial
assessment, or the presence of intact gallbladder were
not found to be related to symptom resolution/improve-
ment by the end of follow-up (data not shown). The
presence of a dilated CBD was not more common
among patients whose symptoms resolved or improved
(52%) compared to those whose symptoms remained
stable or deteriorated (67%) at the end of follow-up (p >
0.05). The proportions of patients reporting symptom
resolution/improvement during follow-up did not differ
significantly (p > 0.05) among patients with SOD type I
(63%), type II (77%), or type III (76%). Among patients
undergoing ERCP, the proportion of patients experien-
cing a post-ERCP complication did not differ signifi-
cantly between patients reporting symptom resolution/
improvement (35%) and those reporting stable or dete-
riorating symptoms (50%) at the end of follow-up (p >
0.05).
Discussion
In the current study, we propose that patients with bili-
ary SOD can be managed without SOM. Although it is
generally accepted that patients with biliary SOD type I
should be treated with biliary sphincterotomy [5,14],
there is some controversy as to the management of bili-
ary type II and III patients. There are only two pub-
lished randomized controlled trials suggesting that
biliary sphincterotomy should be performed in patients
with biliary SOD type II or III found to have raised
basal biliary Sphincter of Oddi pressure upon SOM
[15,16]. However, one of the trials only included type II
patients [15] whilst the other mainly included type II







Symptom status at last follow-up Recurrence
Deterioration Unchanged Improvement Resolution
SOD I (n = 8) 12.5 (7-30) 7 (87.5%) 6 (75%) 1 (12.5%) 2 (25%) 3 (37.5%) 2 (25%) 2 (25%)
SOD II (n = 30) 24 (5-41) 28 (93%) 16 (53%) 0 7 (23%) 20 (67%) 3 (10%) 8 (27%)
dilated CBD (n =
25)
24 (13-40) 23 (92%) 16 (64%) 0 7 (28%) 15 (60%) 3 (12%) 7 (28%)
non-dilated CBD
(n = 5)
28 (13-92) 5 (100%) 0 0 0 5 (100%) 0 1 (20%)
SOD III (n = 21) 12 (8-26) 21 (100%) 1 (5%) 1 (5%) 4 (19%) 12 (57%) 4 (19%) 2 (10%)
All patients (n =
59)
15 (6-35) 56 (95%) 23 (39%) 2 (3.4%) 13 (22%) 35 (59.3%) 9 (15.3%) 12 (20%)
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[16] rendering their results hard to generalize to all
SOD types. Their findings, moreover, are not in line
with uncontrolled studies that failed to show any corre-
lation between SOM results and outcome of
sphincterotomy [6,7]. Also, it has been suggested that
although abnormally elevated pressure at SOM may pre-
dict benefit from biliary sphincterotomy in type II and
III patients, the reverse may not hold true [8] and that a
single negative SOM study does not rule out sphincter
Table 3 Risk factors for post-ERCP pancreatitis and outcome of patients undergoing endoscopic sphincterotomy
(n = 23)





















1 Female 49 I 50 4
a Yes No No effect No
2 Female 66 II 89 1 Yes Yes No effect pancreatitis
3 Male 34 III 0 1 Yes No No effect pancreatitis
4 Female 29 II 37 2
b No No Improvement Yes No
5 Female 36 I 16 2 Yes Yes Resolution No pancreatitis
(1st ERCP)
6 Female 27 I 10 1 No No Improvement No No
7 Female 44 II 27 1 Yes Yes No effect retroperitoneal
perforation
8 Female 47 II 39 2
c Yes No No effect pancreatitis
(2nd ERCP)
9 Female 49 II 24 1 No Yes Resolution No No
10 Female 44 II 22 1 No No Improvement No No
11 Female 46 II 56 2
d No No No effect No
12 Female 49 II 43 2
e No No No effect No
13 Female 47 II 60 4
f No No No effect No
14 Female 26 I 13 1 No No Resolution No No
15 Female 46 II 15 1 No No No effect No
16 Female 52 II 34 2
g Yes No Improvement Yes No
17 Female 57 II 28 1 No No Improvement Yes pancreatitis
18 Female 67 II 35 1 No No Resolution Yes No
19 Female 55 II 49 4
h Yes No Resolution Yes No
20 Female 46 II 92 3
i No No Resolution Yes pancreatitis
(1st ERCP)
21 Female 27 II 110 7
j No No Improvement Yes No
22 Female 29 I 35 3
k Yes No Improvement Yes pancreatitis
(3rd ERCP)
23 Female 43 I 2 2 No Yes Improvement Yes pancreatitis
(1st ERCP)
Conventional over-the-wire biliary sphincterotomy was performed in all patients. In some patients, pre-cut sphincterotomy was performed to obtain access to the
common bile duct prior to conventional sphincterotomy. The pre-cut and conventional sphincterotomy were performed during the same procedure apart from
patient no 5 and 23 in whom they were performed a few weeks apart from each other as access to the common bile duct was achieved on a subsequent
procedure a few weeks after pre-cut sphincterotomy.
a2nd ERCP, sphincterotomy extended; 3rd ERCP, trial of stent; 4th ERCP, stent removal as it was ineffective.
b2nd ERCP for pancreatic sphincter of Oddi manometry showing raised pressure, pancreatic sphincterotomy performed leading to symptom improvement.
c2nd ERCP, sphincterotomy assessed to be inadequate and was widened with no effect on symptoms.
d2nd ERCP showed patent sphincterotomy, no endotherapy performed.
e2nd ERCP for pancreatic SOM but pancreatic duct cannulation failed.
f2nd ERCP done as pancreatic duct appeared dilated on follow-up MRCP. Pancreatic orifice appeared stenosed. No endotherapy performed as pancreatic stent
could not be inserted despite deep guide wire pancreatic duct cannulation; 3rd ERCP for repeat attempt to perform pancreatic sphincterotomy, instrument
failure during procedure; 4th ERCP pancreatic stenting and pancreatic sphincterotomy achieved leading to improvement in symptoms.
g2n ERCP for pancreatic SOM normal pancreatic pressure thus no endotherapy performed.
h2nd ERCP showed re-stenosed biliary sphincterotomy, biliary stenting performed; 3rd ERCP cholangitis due to stent obstruction, re-stenting; 4th ERCP extended
sphincterotomy.
i2nd ERCP showed patent sphincterotomy, biliary stenting performed; 3rd ERCP removal of stent as ineffective.
j2nd ERCP, patent sphincterotomy, biliary stenting which was effective; 3rd-7th ERCP stent changes until surgery (choledochojejunostomy).
k2nd ERCP done for pancreatic sphincter of Oddi manometry, raised pancreatic pressure found and pancreatic sphincterotomy performed with improvement in
symptoms; 3rd ERCP done due to symptom recurrence showed patent sphincterotomies, referred for surgery (open transduodenal sphincteroplasty).
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found that manometric findings compatible with sphinc-
ter of Oddi dysfunction, probably due to its episodic
nature, are poorly reproducible [18]. A recent study,
involving a decision analysis model constructed using a
software program, showed that empirical biliary sphinc-
terotomy may be more cost-effective in comparison to a
strategy based on the results of manometry for patients
with biliary type II pain [19].
In our cohort, a total of 44/59 patients (75%) reported
subjective symptomatic benefit after a median follow-up
of 15 months. This proportion is similar to that
reported in the literature [1-3,16,20-22].
The risk of complications, in particular pancreatitis, is
of concern in patients with SOD undergoing ERCP/
sphincterotomy [9-11]. The occurrence of post-ERCP
complications in our study was 18% in general and 16%
for post-ERCP pancreatitis in particular, which is com-
parable to that in previous reports [1,3,10,22]. Having a
post-ERCP complication was not found to have any sig-
nificant effect on symptomatic relief at follow-up. Place-
ment of temporary prophylactic pancreatic duct stents
has been suggested to reduce post-ERCP pancreatitis
rates in patients with SOD [23,24]. However, this was
not performed in the current study, and thus we cannot
exclude the possibility that pancreatic duct stenting
might have reduced the incidence of pancreatitis.
There is certain evidence suggesting that the etiology
of pain in SOD may be multifactorial. Eighty-five per-
cent of patients continued to have pain at last follow-up
with 34% requiring opiate analgesics for pain control
(mainly mild opiates). This is in keeping with a previous
study in which, despite endoscopic sphincterotomy, 82%
of patients with biliary type pain continued to have pain
after a mean follow-up of 18 months, indicating that
SOD may be a chronic pain disorder with a multifactor-
ial etiology [2]. Duodenal specific visceral hyperalgesia
[25] and delayed gastric emptying [3] may be involved
in the pathogenesis of pain in these patients. Further-
more, in our cohort 20% of patients experienced at least
one recurrence of symptoms after initial response to
therapy. Although it has been previously reported that
restenosis after endoscopic sphincterotomy for SOD
requiring repeated intervention may occur in 13% - 61%
during a follow-up of 19 months and 26 months respec-
tively [1,3], ours is the first study to quantify the propor-
tion of patients with biliary type pain who relapse after
combined medical and endoscopic management. Further
studies, are warranted to fully elucidate the potential
mechanisms of abdominal pain in SOD and the role
sphincterotomy may play as a component of a compre-
hensive pain management.
We did not find any differences in response to therapy
between the different subclassifications of SOD. This is
in keeping with several studies showing that this classifi-
cation may be inadequate to predict treatment outcome
[2,3,20]. It should, however, be noted that a revised ver-
sion of the initial classification is used nowadays in
which noninvasive methods, instead of ERCP, are used
to measure CBD diameter and contrast drainage times
a r en ol o n g e ru t i l i z e d[ 5 ] .T oo u rk n o w l e d g e ,t h i s
revised classification system has not been formally
validated.
The presence of an intact gallbladder in our series did
not affect symptomatic relief at follow-up. Fifty-six per-
cent of the patients had an intact gallbladder in situ but
no gallstones were identified on ultrasound or MRCP/
ERCP. Although there are only limited data on SOD
and its treatment in patients with gallbladder in situ,
SOD is thought to occur in these patients [5]. SOM stu-
dies have shown elevated sphincter pressures in a pro-
portion of patients with biliary pain and intact
gallbladder [26,27]. Also, endoscopic sphincterotomy has
been shown to be effective in patients with biliary-type
pain and gallbladder in situ [26,27]. However, radionu-
clide imaging for gallbladder dyskinesia was not per-
formed in our cohort and thus we cannot exclude that
some of the patients with an intact gallbladder might
have benefited from cholecystectomy.
Certain methodological limitations should be taken
into consideration when interpreting the results of the
current study. Although consecutive patients were pro-
spectively identified, part of the data analyzed were ret-
rospectively collected from patient files and no validated
questionnaire or structured interview was uniformly
used to define treatment outcome. However, all patients
were treated in a uniform fashion in a single center
under the care of a single consultant gastroenterologist
(RWC). Furthermore, discharged patients were not con-
tacted to obtain follow-up data post-discharge. Although
we would have expected these patients to have been re-
referred to our institution in the event of significant
change in symptoms we cannot fully exclude the possi-
bility that some discharged patients who relapsed may
have been treated elsewhere. Also, the current study was
observational. Large prospective interventional trials
enrolling patients with SOD of all types are needed in
order to study the most appropriate management
approach for these patients. Our data, as well as those
published by others [2,3,20], suggest that SOM results
m a yn o tn e c e s s a r i l yd e f i n et h em a n a g e m e n tc o u r s ei n
such future trials.
Conclusions
In conclusion, patients with biliary sphincter of Oddi
disorder may be managed with a combination of endo-
scopic sphincterotomy (performed in those with dilated
common bile duct) and medical therapy without
Kalaitzakis et al. BMC Gastroenterology 2010, 10:124
http://www.biomedcentral.com/1471-230X/10/124
Page 6 of 8utilization of SOM. The results of this approach with
regards to symptomatic relief and ERCP complication
rate are comparable to those published in the literature.
However, a significant proportion of patients continued
to have pain despite subjective symptomatic improve-
ment. Prospective randomized interventional trials
enrolling patients with SOD of all types are needed in
order to study the most appropriate management
approach for these patients.
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